These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21411521)

  • 1. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.
    Lynch JB; Nduati R; Blish CA; Richardson BA; Mabuka JM; Jalalian-Lechak Z; John-Stewart G; Overbaugh J
    J Virol; 2011 Jun; 85(11):5252-61. PubMed ID: 21411521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.
    Ghulam-Smith M; Olson A; White LF; Chasela CS; Ellington SR; Kourtis AP; Jamieson DJ; Tegha G; van der Horst CM; Sagar M
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission.
    Doepker LE; Simonich CA; Ralph D; Shipley MM; Garrett M; Gobillot T; Vigdorovich V; Sather DN; Nduati R; Matsen FA; Overbaugh JM
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.
    Milligan C; Omenda MM; Chohan V; Odem-Davis K; Richardson BA; Nduati R; Overbaugh J
    mBio; 2016 Feb; 7(1):e02221-15. PubMed ID: 26838723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.
    Mabuka J; Goo L; Omenda MM; Nduati R; Overbaugh J
    AIDS; 2013 Jun; 27(10):1535-44. PubMed ID: 23856624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.
    Chaillon A; Wack T; Braibant M; Mandelbrot L; Blanche S; Warszawski J; Barin F
    J Virol; 2012 Oct; 86(19):10540-6. PubMed ID: 22811522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission.
    Thomas AS; Coote C; Moreau Y; Isaac JE; Ewing AC; Kourtis AP; Sagar M
    JCI Insight; 2022 May; 7(9):. PubMed ID: 35324477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection.
    Omenda MM; Milligan C; Odem-Davis K; Nduati R; Richardson BA; Lynch J; John-Stewart G; Overbaugh J
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):163-6. PubMed ID: 23774880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.
    Russell ES; Ojeda S; Fouda GG; Meshnick SR; Montefiori D; Permar SR; Swanstrom R
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):511-5. PubMed ID: 23075434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
    Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
    PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
    Rudicell RS; Kwon YD; Ko SY; Pegu A; Louder MK; Georgiev IS; Wu X; Zhu J; Boyington JC; Chen X; Shi W; Yang ZY; Doria-Rose NA; McKee K; O'Dell S; Schmidt SD; Chuang GY; Druz A; Soto C; Yang Y; Zhang B; Zhou T; Todd JP; Lloyd KE; Eudailey J; Roberts KE; Donald BR; Bailer RT; Ledgerwood J; ; Mullikin JC; Shapiro L; Koup RA; Graham BS; Nason MC; Connors M; Haynes BF; Rao SS; Roederer M; Kwong PD; Mascola JR; Nabel GJ
    J Virol; 2014 Nov; 88(21):12669-82. PubMed ID: 25142607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
    Nandi A; Lavine CL; Wang P; Lipchina I; Goepfert PA; Shaw GM; Tomaras GD; Montefiori DC; Haynes BF; Easterbrook P; Robinson JE; Sodroski JG; Yang X;
    Virology; 2010 Jan; 396(2):339-48. PubMed ID: 19922969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.
    Russell ES; Kwiek JJ; Keys J; Barton K; Mwapasa V; Montefiori DC; Meshnick SR; Swanstrom R
    J Virol; 2011 Aug; 85(16):8253-62. PubMed ID: 21593171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.
    Nakamura KJ; Cerini C; Sobrera ER; Heath L; Sinkala M; Kankasa C; Thea DM; Mullins JI; Kuhn L; Aldrovandi GM
    AIDS; 2013 Jan; 27(3):337-46. PubMed ID: 23296195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.